生殖医学杂志

参考文献

[1] Sung H,Ferlay J,Siegel RL,et al.Global cancer statistics 2020:globocan estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J].CA Cancer J Clin,2021,71:209-249.

[2] Alfano CM,Leach CR,Smith TG,et al.Equitably improving outcomes for cancer survivors and supporting caregivers:A blueprint for care delivery,research,education,and policy[J].CA Cancer J Clin,2019,69:35-49.

[3] Siegel RL,Miller KD,Jemal A.Cancer statistics,2018[J].CA Cancer J Clin,2018,68:7-30.

[4] 叶云，陈昂，刘哲.医院员工生育力保存认知度现状及其影响因素的调查[J].生殖医学杂志，2020,29:1603-1611.

[5] Griffiths MJ,Winship AL,Hutt KJ.Do cancer therapies damage the uterus and compromise fertility?[J].Hum Reprod Update,2020,26:161-173.

[6] Taylan E,Oktay K.Fertility preservation in gynecologic cancers[J].Gynecol Oncol,2019,155:522-529.

[7] Gay C,Raphael YR,Steers J,et al.Ovarian transposition before pelvic radiation therapy:spatial distribution and dose volume analysis[J].Adv Radiat Oncol,2021,7:100804.

[8] 孔为民，商若天，索红燕.放疗对妇科恶性肿瘤生殖和内分泌功能的影响及防治[J].中国实用妇科与产科杂志，2019,35:635-638.

[9] 中华医学会生殖医学分会.生育力保存中国专家共识[J].生殖医学杂志，2021,30:1129-1134.

[10] Hoekman EJ,Broeders EABJ,Louwe LA,et al.Ovarian function after ovarian transposition and additional pelvic radiotherapy:A systematic review[J].Eur J Surg Oncol,2019,45:1328-1340.

[11] Jung W,Kim YH,Kim KS.Ovarian function preservation in patients with cervical cancer undergoing hysterectomy and ovarian transposition before pelvic radiotherapy[J].Technol Cancer Res Treat,2021,20:1-9.

[12] Koh WJ,Abu-Rustum NR,Bean S,et al.Cervical cancer,version 3.2019,NCCN clinical practice guidelines in oncology[J].J Natl Compr Canc Netw,2019,17:64-84.

[13] Nezhat C,Roman RA,Rambhatla A,et al.Reproductive and oncologic outcomes after fertility-sparing surgery for early stage cervical cancer:a systematic review[J].Fertil Steril,2020,113:685-703.

[14] 李承尧，李圃.妇科常见恶性肿瘤保留生育功能的研究进展[J].国际妇产科学杂志，2022,49:196-201.

[15] Armstrong DK,Alvarez RD,Bakkum-Gamez JN,et al.Ovarian cancer,version 2.2020,NCCN clinical practice guidelines in oncology[J].J Natl Compr Canc Netw,2021,19:191-226.

[16] Santos ML,Pais AS,Almeida Santos T.Fertility preservation in ovarian cancer patients[J].Gynecol Endocrinol,2021,37:483-489.

[17] 周琦，吴小华，刘继红，等.子宫内膜癌诊断与治疗指南(第4版)[J].中国实用妇科与产科杂志，2018,34:880-886.

[18] 魏琳萍，裴澄，唐宇星，等.子宫内膜不典型增生及早期子宫内膜样腺癌患者保留生育功能治疗的研究[J].中国实用妇科与产科杂志，2020,36:173-176.

[19] Somigliana E,Mangili G,Martinelli F,et al.Fertility preservation in women with cervical cancer[J].Crit Rev Oncol Hematol,2020,154:103092.

[20] 吕小慧，陈必良.达芬奇机器人手术系统在妇科手术中的应用[J].机器人外科学杂志，2020,1:57-60,18.

[21] Reiser E,B?ttcher B,Minasch D,et al.Ovarian transposition[J].Memo,2020,13:413-415.

[22] Chung RK,Salari S,Findley J,et al.Uterine transplantation:recipient patient populations[J].Clin Obstet Gynecol,2022,65:15-23.

[23] Harada M,Osuga Y.Fertility preservation for female cancer patients[J].Int J Clin Oncol,2019,24:28-33.

[24] 周蓉，鹿群，刘国莉，等.早期子宫内膜癌保留生育功能治疗专家共识[J].中国妇产科临床杂志，2019,20:369-373.

[25] 王秋毅，朱慧莉，黄薇，等.女性恶性肿瘤患者的生育力保护策略[J].中国计划生育学杂志，2021,29:207-210.

[26] Prasath EB,Chan ML,Wong WH,et al.First pregnancy and live birth resulting from cryopreserved embryos obtained from in vitro matured oocytes after oophorectomy in an ovarian cancer patient[J].Hum Reprod,2014,29:276-278.

[27] 马聪，邹慧娟，王建业，等.自体卵巢组织冷冻在女性肿瘤患者生育力保存中的应用[J].生殖医学杂志，2020,29:663-667.

[28] 郑峥，姚吉龙.女性生育力保存和保护的热点问题[J].中国实用妇科与产科杂志，2019,35:775-779.

[29] Dolmans MM,Donnez J.Fertility preservation in women for medical and social reasons:oocytes vs ovarian tissue[J].Best Pract Res Clin Obstet Gynaecol,2021,70:63-80.

[30] 陈美一，邵茵，马利国.冷冻保存卵巢组织移植术对年轻宫颈癌患者卵巢内分泌功能的影响[J].中国生育健康杂志，2017,28:273-276.

[31] Van der Ven H,Liebenthron J,Beckmann M,et al.Ninety-five orthotopic transplantations in 74 women of ovarian tissue after cytotoxic treatment in a fertility preservation network:tissue activity,pregnancy and delivery rates[J].Hum Reprod,2016,31:2031-2041.

[32] 国际妇科内分泌学会中国妇科内分泌学会及共识专家.卵巢组织冻存与移植中国专家共识[J].中国临床医生杂志，2018,46:496-500.

[33] 徐蓓，靳镭.现阶段中国实行选择性单胚胎移植的时机是否成熟[J].生殖医学杂志，2018,27:879-883.

[34] 赵全凤，符佩姝，谷文睿，等.GnRHa用于化疗后生育力保护的循证医学研究进展[J].中国临床药理学与治疗学，2021,26:1449-1454.

[35] Senra JC,Roque M,Talim M,et al.Gonadotropin-releasing hormone agonists for ovarian protection during cancer chemotherapy:systematic review and meta-analysis[J].Ultrasound Obstet Gynecol,2018,51:77-86.

[36] Oktay K,Harvey BE,Partridge AH,et al.Fertility preservation in patients with cancer:ASCO clinical practice guideline updat[J].J Clin Oncol,2018,36:1994-2001.

[37] 赵晓莉.早期子宫内膜癌患者保留生育功能治疗的Meta分析[D].石家庄：河北医科大学，2020.

[38] Zhou H,Cao D,Yang J,et al.Gonadotropin-releasing hormone agonist combined with a levonorgestrel- releasing intrauterine system or letrozole for fertility-preserving treatment of endometrial carcinoma and complex atypical hyperplasia in young women[J].Int J Gynecol Cancer,2017,27:1178-1182.

[39] Chan JL,Letourneau J,Salem W,et al.Regret around fertility choices is decreased with pre-treatment counseling in gynecologic cancer patients[J].J Cancer Surviv,2017,11:58-63.

[40] Yu L,Peterson B,Inhorn MC,et al.Knowledge,attitudes,and intentions toward fertility awareness and oocyte cryopreservation among obstetrics and gynecology resident physicians[J].Hum Reprod,2016,31:403-411.

[41] Gorostidi M,Gil-Ibaňez B,Alonso S,et al.Fertility preservation treatment of gynecological cancer patients in Spain:a national survey[J].Arch Gynecol Obstet,2020,301:793-800.

[42] Zhang H,Wang G,Jiang B,et al.The knowledge,attitude,and self-reported behaviors of oncology physicians regarding fertility preservation in adult cancer patients[J].J Cancer Educ,2020,35:1119-1127.